SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 233 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,569,908 | -8.7% | 455,927 | -0.5% | 0.00% | 0.0% |
| Q2 2023 | $13,768,081 | -22.1% | 458,020 | -6.2% | 0.00% | -25.0% |
| Q1 2023 | $17,685,131 | -3.0% | 488,135 | -4.5% | 0.00% | 0.0% |
| Q4 2022 | $18,228,262 | +3.3% | 511,025 | -2.0% | 0.00% | 0.0% |
| Q3 2022 | $17,643,000 | +19.3% | 521,227 | +1.9% | 0.00% | +33.3% |
| Q2 2022 | $14,792,000 | -16.1% | 511,504 | -6.2% | 0.00% | 0.0% |
| Q1 2022 | $17,626,000 | +10.6% | 545,371 | -0.2% | 0.00% | 0.0% |
| Q4 2021 | $15,939,000 | -3.2% | 546,622 | -11.4% | 0.00% | 0.0% |
| Q3 2021 | $16,458,000 | -12.3% | 617,120 | +1.3% | 0.00% | -25.0% |
| Q2 2021 | $18,760,000 | +9.1% | 609,294 | -7.2% | 0.00% | 0.0% |
| Q1 2021 | $17,192,000 | +4.1% | 656,678 | +0.1% | 0.00% | 0.0% |
| Q4 2020 | $16,512,000 | +19.9% | 656,251 | -0.7% | 0.00% | +33.3% |
| Q3 2020 | $13,777,000 | -15.5% | 661,107 | -3.7% | 0.00% | -25.0% |
| Q2 2020 | $16,298,000 | +30.7% | 686,219 | -1.0% | 0.00% | 0.0% |
| Q1 2020 | $12,471,000 | -26.8% | 693,226 | -3.5% | 0.00% | 0.0% |
| Q4 2019 | $17,048,000 | -37.8% | 718,719 | -27.9% | 0.00% | -50.0% |
| Q3 2019 | $27,410,000 | -19.5% | 997,458 | -3.1% | 0.01% | -11.1% |
| Q2 2019 | $34,061,000 | -6.6% | 1,029,359 | -1.1% | 0.01% | -10.0% |
| Q1 2019 | $36,457,000 | -9.1% | 1,040,439 | -13.8% | 0.01% | -23.1% |
| Q4 2018 | $40,086,000 | -36.6% | 1,206,632 | -3.9% | 0.01% | -18.8% |
| Q3 2018 | $63,238,000 | -26.9% | 1,255,961 | -13.1% | 0.02% | -33.3% |
| Q2 2018 | $86,466,000 | +27.2% | 1,444,720 | -2.7% | 0.02% | +26.3% |
| Q1 2018 | $67,971,000 | +19.5% | 1,484,099 | +3.9% | 0.02% | +26.7% |
| Q4 2017 | $56,903,000 | -4.1% | 1,427,928 | -3.7% | 0.02% | -6.2% |
| Q3 2017 | $59,321,000 | -11.0% | 1,483,046 | -4.1% | 0.02% | -15.8% |
| Q2 2017 | $66,646,000 | +27.6% | 1,546,329 | -7.3% | 0.02% | +35.7% |
| Q1 2017 | $52,236,000 | +30.0% | 1,668,864 | +4.9% | 0.01% | +16.7% |
| Q4 2016 | $40,167,000 | -4.1% | 1,590,780 | -6.1% | 0.01% | 0.0% |
| Q3 2016 | $41,892,000 | +23.9% | 1,694,026 | +2.1% | 0.01% | +20.0% |
| Q2 2016 | $33,806,000 | +79.4% | 1,659,604 | +34.3% | 0.01% | +66.7% |
| Q1 2016 | $18,847,000 | +130.3% | 1,235,769 | +103.0% | 0.01% | +200.0% |
| Q4 2015 | $8,183,000 | +4.2% | 608,894 | +8.8% | 0.00% | 0.0% |
| Q3 2015 | $7,850,000 | +22.9% | 559,492 | +48.7% | 0.00% | 0.0% |
| Q2 2015 | $6,387,000 | +308.1% | 376,192 | +190.5% | 0.00% | – |
| Q1 2015 | $1,565,000 | +47.6% | 129,501 | +1.4% | 0.00% | – |
| Q4 2014 | $1,060,000 | -15.1% | 127,692 | -11.1% | 0.00% | – |
| Q3 2014 | $1,248,000 | -54.3% | 143,608 | -42.4% | 0.00% | – |
| Q2 2014 | $2,732,000 | +292.5% | 249,492 | +220.4% | 0.00% | – |
| Q1 2014 | $696,000 | +50.3% | 77,873 | +26.7% | 0.00% | – |
| Q4 2013 | $463,000 | -45.1% | 61,474 | -46.6% | 0.00% | – |
| Q3 2013 | $844,000 | +83.9% | 115,098 | +61.2% | 0.00% | – |
| Q2 2013 | $459,000 | – | 71,420 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |